COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
In: Journal of Allergy and Clinical Immunology, Jg. 147 (2021-03-01), S. 870-870
Online
unknown
Zugriff:
Background As of November 2020, SARS-CoV-2 has resulted in 55 million infections worldwide and over 1.3 million deaths from COVID-19. Outcomes following SARS-CoV-2 infection in individuals with primary immunodeficiency or symptomatic secondary immunodeficiency remain uncertain. Objectives To document the outcomes of individuals with primary or symptomatic secondary immunodeficiency following COVID-19 in the United Kingdom. Methods At the start of the COVID-19 pandemic, the United Kingdom Primary Immunodeficiency Network (UK PIN) established a registry of cases to collate the nationwide outcomes of COVID-19 in individuals with PID or symptomatic SID and determine risk factors associated with morbidity and mortality from COVID-19 in these patient groups. Results 100 patients had been enrolled by 1st July 2020, 60 with primary immunodeficiency (PID), 7 with other inborn errors of immunity including autoinflammatory diseases and C1 inhibitor deficiency and 33 with symptomatic secondary immunodeficiency (SID). In individuals with PID, 53.3% (n=32/60) were hospitalized, the infection fatality rate (IFR) was 20.0% (n=12/60), the case fatality rate (CFR) was 31.6% (n=12/38) and the inpatient mortality 37.5% (n=12/32). Individuals with SID had worse outcomes than those with PID. 75.8% (n=25/33) were hospitalized, the IFR was 33.3% (n=11/33), the CFR was 39.2% (n=11/28), and inpatient mortality 44.0% (n=11/25). Conclusions In comparison to the general population, adult patients with PID and symptomatic SID display greater morbidity and mortality from COVID-19. This increased risk must be reflected in public health guidelines to adequately protect vulnerable patients from exposure to the virus.
Capsule summary: This large case series of outcomes following COVID-19 demonstrates that, in comparison to the general population, adults with primary and secondary immunodeficiencies are at increased risk of morbidity and mortality following SARS-CoV-2 infection.
Titel: |
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
|
---|---|
Autor/in / Beteiligte Person: | Philip D Bright ; Cleave, Betsy ; Devlin, Lisa ; Vaitla, Prashantha M. ; O’Brien, Rachael ; Dempster, John ; Murng, Sai ; Arumugakani, Gururaj ; Patel, Smita ; MacLochlainn, Dylan ; Dziadzio, Magdalena ; Ag, Richter ; Morsi, Hadeil ; Kenneth F Baker ; Bermingham, William H. ; Burns, Siobhan O. ; Savic, Sinisa ; Christopher J A Duncan ; Bhole, Malini ; Shrimpton, Anna ; Drewe, Elizabeth ; Boules, Evon ; Johnston, Sarah ; Gennery, Andrew R. ; Anantharachagan, Ariharan ; Noorani, Sadia ; Huissoon, Aarnoud ; Shields, Adrian ; Hayman, Grant ; Bahal, Sameer ; Elkhalifa, Shuayb ; Dhalla, Fatima ; Richter, Alex G. ; Grigoriadou, Sofia ; Stroud, Catherine ; Jain, Rashmi ; Leeman, Lucy ; Herwadkar, A ; Verma, Nisha ; Goddard, Sarah ; McDermott, Elizabeth ; Seneviratne, Suranjith L. ; Misbah, Siraj A. ; Price, Arthur ; Jolles, Stephen ; Adrian M Shields ; Mahabir, Shanti |
Link: | |
Zeitschrift: | Journal of Allergy and Clinical Immunology, Jg. 147 (2021-03-01), S. 870-870 |
Veröffentlichung: | Elsevier BV, 2021 |
Medientyp: | unknown |
ISSN: | 0091-6749 (print) |
DOI: | 10.1016/j.jaci.2020.12.620 |
Schlagwort: |
|
Sonstiges: |
|